Cancer Vaccines

New research on cancer vaccines from J.R. Nair and co-authors summarized

Published in Cancer Weekly, November 6th, 2007

"Angiogenesis, the growth of new blood vessels, is essential for tumor growth and metastasis. Of the several known angiogenic factors, VEGF is an important mediator of tumor-induced angiogenesis and represents a potential target for innovative anticancer therapy," scientists writing in the journal Expert Review of Vaccines report.

"Recently, humanized monoclonal anti-VEGF antibody (bevacizumab) has been approved by the US FDA for combinatorial therapies with cytotoxic drugs in metastatic colorectal cancer. However, adverse side effects and enormous costs are associated with the use and delivery of bevacizumab. In the study under evaluation, Rod et al....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry